All posts by imreal

CoWorx Staffing Services Announces Tim Hartnett as President and CEO


News Image

“It is an honor to join the executive team of one of the nation’s largest and most well-respected staffing agencies,” said CoWorx Staffing Services CEO Tim Hartnett.

CoWorx Staffing Services announces Tim Hartnett as its President and Chief Executive Officer.

Hartnett spent the majority of his career at PricewaterhouseCoopers (PwC), a multinational professional services network, where he served as Global and U.S. Private Equity Leader; and throughout his career, he has focused on acquisitions and growing companies through operational improvements.

“It is an honor to join the executive team of one of the nation’s largest and most well-respected staffing agencies,” said CoWorx Staffing Services CEO Tim Hartnett. “We are committed to investing in the company’s growth, our exceptional team and continue providing best-in-class service to our clients.”

About CoWorx

For 45 years, CoWorx Staffing Services has been helping job seekers grow their careers and employers build their workforce. CoWorx places candidates nationwide in administrative, light industrial, call center, and distribution and 3rd-party logistics positions, with an additional luxury beauty and fragrance division. Dedicated to workplace safety and with an ongoing commitment to diversity and partnership, CoWorx consistently earns Safety Standard of Excellence marks from the ASA and ranks among the largest staffing firms in the U.S., boasting more than 80 offices and 50,000 field employees nationally. The CoWorx philosophy, “Together we’re better,” embodies the company’s commitment to working collaboratively with clients, internal staff and field employees. To learn more about CoWorx, visit http://www.coworxstaffing.com.

Share article on social media or email:

ValidCare Launches National Program to Share CBD Real World Evidence with FDA


“The FDA has invited the CBD industry to offer safety and efficacy data to support its science-based approach to regulations,” said Vince Saunders, CEO of CBDAmerican Shaman. “We are excited to gather and share additional data through a trusted, independent party. Transparency is good for everyone.”

ValidCare, the market intelligence platform for the canna-based product industry, announced a first-of-its-kind National Consumer Experience Program to gather CBD Real World Evidence (RWE) directly from consumers through November, 2019. The goal of the industry-wide program is to collect large amounts of consumer data via its CBD+me™ app to inform the U.S. Food and Drug Administration’s (FDA) questions on the safety and efficacy of cannabis-derived products. Data will be shared with the FDA while protecting company-specific intellectual property and consumer identities.

Recent comments from the FDA reinforce the need for safety and efficacy data to appropriately regulate the pathway for hemp-derived cannabidiol (CBD). Lowell Schiller, Principal Associate Commissioner for Policy at FDA, suggested CBD should stand for “Collect Better Data” when speaking at a hemp industry event in mid-August(1). “The FDA has invited the CBD industry to offer safety and efficacy data to support its science-based approach to regulations,” said Vince Saunders, CEO of CBDAmerican Shaman. “We shared significant in-house data with FDA during the comment period in July. Now, we are excited to gather and share additional data through a trusted, independent party. Transparency is good for everyone. We appreciate ValidCare’s sponsorship and encourage all CBD brands to join this important program.”

ValidCare has invited participation by all CBD product companies, including members of US Hemp Roundtable, Hemp Industries Association and/or those having achieved US Hemp Authority certification. The following companies have enrolled to date: Barleans, CBDAmerican Shaman, CBDistillery, Comfort Leaf, Elixinol, Functional Remedies, GenCanna Global, Lazarus Botanicals, MedTerra, Queen City Infusions and Restorative Botanicals.

These companies are inviting their customers to download a branded version of ValidCare’s free CBD+me app, then track their experiences with cannabis-derived products. Companies will have access to CBD Real World Evidence related to their products and consumers. “It is great to see so many leading brands demonstrate confidence in their products and their commitment to American consumers and the regulatory process. Their leadership will help benefit the entire industry,” said Patrick McCarthy, CEO, ValidCare.

“Our industry is at a critical juncture and needs to work with FDA to help validate the efficacy of hemp-derived products and instill consumer confidence in product quality,” said Chase Terwilliger, CEO, CBDistillery. “With our commitment to product quality and safety for consumers, gaining experiential data from our customers can help us create even better products and experiences.”

The CBD+me platform is available to consumers for free in the Apple App Store or Google Play. Consumers set up a profile and wellness goals for themselves or their loved one(s), journal the products they’re using and record the effects, including adverse product event reports.

References

1)    Lowell Schiller, JD, FDA. National Industrial Hemp Council, 2019. https://www.fda.gov/news-events/speeches-fda-officials/remarks-national-industrial-hemp-council-2019-hemp-business-summit-08132019

# # #

About ValidCare

ValidCare, LLC is the market intelligence platform for the cannabis-derived product industry, powered by real-time consumer experiences. Through the ValidCare community, participants including consumers, product suppliers, researchers, and providers, come together to study, educate, measure and document the consumer experience using canna-based products. ValidCare’s proprietary app (CBD+me™) supports ongoing two-way communication, combining self-reported consumer data with advanced machine learning to deliver aggregated insights that help improve product quality, consistency, effectiveness, and the adoption of industry standards. For more information, visit http://www.validcare.com or call 844-825-4322.

Share article on social media or email:

Increasing Consumer Privacy Demand Opens New Doors For Marketers


https://www.prweb.com/

FigLeaf: When Privacy Is A Choice, Humanity Is Free

“The findings of this survey offer marketers and advertisers an opportunity to adjust to the changing privacy landscape and engage consumers in new and more authentic ways,” said Pankaj Srivastava, COO and CMO of FigLeaf.

As the debate rages over consumer online privacy, FigLeaf, a privacy-first company, surveyed US and UK consumers and discovered an underlying opportunity for those hit hardest by ever-increasing privacy demands: marketers and advertisers. Despite the fact that 68% of consumers do not believe online privacy is possible and 52% do not trust recent commitments made by Facebook or Google around stricter privacy protection, the survey revealed consumers are still open to sharing information with brands they trust. Banks ranked highest in trust factor for all respondents, with government entities second. Perhaps unsurprisingly, social media sites like Facebook ranked dead last in trust, with mobile operators faring only slightly better – a particularly telling insight for brands and advertisers when considering the best medium for reaching their consumers.

Survey results also highlighted key differences in individuals’ privacy preferences based on gender and age, creating an opportunity for marketers to more closely align messaging to key demographics.

“The findings of this survey offer marketers and advertisers an opportunity to adjust to the changing privacy landscape and engage consumers in new and more authentic ways,” said Pankaj Srivastava, COO and CMO of FigLeaf. “Consumers have voiced the fact they are not unwilling to share personal data. They simply want greater insight into how that data is used, and they want more choice and control over when they share personal information and with whom. Brands that comply with these wishes, and demonstrate a willingness to respect and protect the individual’s personal information, will be rewarded with deeper engagement and lasting loyalty.”

Gender

Men and women paralleled each other on their reactions to recent data scandals, with more than three-quarters of both men and women saying they have changed the way they behave online. Gender responses also matched in the knowledge of where their personal data exists online, with 28% of women and 29% of men saying they are confident they know every company and website who has access to – or is storing – their online data.

The sexes differ in online privacy however, in what they are willing to share and how they address privacy concerns. For example, 48% percent of women are worried about sharing their location or having it tracked compared to only 37% of men. To address privacy concerns, women are more apt to share less online (68%) as compared to men (54%), while one in 10 men use a Virtual Private Network (VPN) as compared to only 7% of women who do.

Age

When asked who should be responsible for an individual’s privacy, 45% of US respondents agreed it should be a joint effort between the individual, the companies collecting the data, and government regulators. However, when broken down by age, 28% of respondents over 30 years old placed the responsibility squarely on the shoulders of companies, while only 15% under 30 were inclined to agree. Those under 30 showed more inclination to take matters into their own hands, with 58% choosing to use privacy tools, deleting social media accounts or restricting what they share online, as compared to the 30% of respondents over 60 who believed the best solution to protect personal, digital information was for government to create stricter laws.

The younger generation was slightly more bullish on privacy legislation, with 12% saying the advent of the European Union’s General Data Protection Regulation (GDPR) afforded them greater choice over which sites can access their personal information, compared with only 6% of those over 45. The under 45 demographic was also nearly twice as likely to believe total online privacy is possible, compared to their older counterparts.

Overall, respondents under 45 showed a marked optimism for the future of online privacy. One in five felt confident they knew everywhere their information was used or stored online, as compared to only 10% of those over the age of 45. And, while younger respondents recognized their activities were being tracked online, only 11% thought companies were taking advantage of all the information they could access. The under-45 demographic was also nearly twice as likely to believe total online privacy is possible, compared to their older counterparts.

Among all respondents to the survey, 62% believe a privacy tool or cybersecurity measure is the best way to stay safe online, demonstrating a desire to have greater control over their own data. This option proved more effective than restricting online activity (32%), deleting social media (16%), or demanding stricter penalties for companies that violate privacy (38%).

Conducted in May 2019, the survey queried over 4,000 male and female online consumers aged 18 or older across the US and the UK. A FigLeaf press kit including, charts and graphs, logos and other assets can be accessed here.

About FigLeaf

FigLeaf Inc. is a privacy-first company that offers consumers the choice of total digital privacy across all devices, anywhere and anytime. Our comprehensive, easy-to-use privacy solution allows consumers to control their own data, image, reputation and identity online. FigLeaf empowers individuals with the choice for total digital privacy, helping them understand what and where data has been exposed, and providing tools to securely share information in the manner they choose. Available on Mac, Windows, iOS and Android, FigLeaf’s “Privacy by Design” approach gathers only the information a consumer chooses to share. Our proprietary “zero-knowledge” solution architecture ensures only the individual consumer holds the key to their identity and no outside party can access their personal information – not even FigLeaf.

Founded in 2018, FigLeaf is a privately held company with offices in Silicon Valley, London, Kiev and Nicosia, Cyprus. Follow FigLeaf on Facebook, Twitter, Instagram and LinkedIn, or visit us at https://figleaf.com to learn more. FigLeaf: when privacy is a choice, humanity is free.

All trademarks contained herein are the property of their respective owners.

Share article on social media or email:



Synapse Technology Engages Government Customers in Partnership with Federal Resources


Syntech ONE is an AI-powered software platform that dramatically improves the effectiveness of checkpoint X-ray scanners by automating detection of prohibited items.

Artificial intelligence (AI) security and defense company Synapse Technology Corporation today announced it has expanded its sales and distribution reach across US federal customers via a partnership with distributor Federal Resources. Federal Resources will market, sell and support the company’s Syntech ONE platform for applications including aviation security, border security, and critical infrastructure protection.

Federal Resources is a solutions provider serving the Department of Defense, various Federal Agencies and first responders in various markets to include the Critical Infrastructure market. “Federal Resources is excited to be partnering with Synapse Technology to bring their revolutionary AI technology to new and existing Federal Government users to expand their training and X-ray interpretation capabilities for an expanding threat base. Syntech ONE will be one of Federal Resources’ flagship products within our Critical Infrastructure market. Adding this product to our portfolio will greatly enhance our ability to help the effectiveness of operator screening for threat detection. We’re thrilled to be able to demonstrate the Syntech ONE at our offices in Arlington, VA,” commented Matt Birnbaum, VP of Vertical Sales of Federal Resources.

Syntech ONE is an AI-powered software platform that dramatically improves the effectiveness of checkpoint X-ray scanners by automating detection of prohibited items. It retrofits onto both new and existing X-ray systems. Its growing threat detection library, which now includes ammunition in addition to gun components, sharps and knives, is the most extensive in the industry. Syntech ONE’s performance is superior to other commercially-available systems. Syntech ONE is deployed in live screening environments for aviation and critical infrastructure protection and has processed over 17,000,000 passenger bags. The US Department of Homeland Security (DHS) recognizes the value of Syntech ONE and has granted Synapse Technology Corporation a SAFETY Act award for its technology platform. In addition, the US Airforce recently awarded Synapse a contract, which allows US DOD and other US government customers to easily acquire the advanced software.

“Federal Resources is the perfect partner for Synapse. As we further build our federal customer relationships, Federal Resources puts us in the perfect position to deploy Synapse Technology throughout the United States government. In conjunction with our recent investment from In-Q-Tel, we are in a prime position to rapidly modernize security checkpoints with artificial intelligence.” commented Ian Cinnamon, President of Synapse Technology Corporation.

Synapse Technology recently entered into a strategic investment agreement with In-Q-Tel (IQT), the not-for-profit strategic investor that accelerates the development and delivery of cutting-edge technologies to U.S. intelligence and defense agencies. “Synapse’s technology is disrupting the industry by using artificial intelligence to automatically identify threats at our country’s air, sea, and land ports of entry,” said A.J. Bertone, Partner, Investments, IQT.

About Synapse Technology

Synapse Technology’s AI platform Syntech ONE® integrates with new and existing X-ray machines used at security checkpoints. Instead of security screeners relying solely on human cognitive abilities to identify threats like guns and knives, Syntech ONE augments and automates the detection of these dangerous items. Syntech ONE has already been widely deployed, having processed over 17,000,000 passenger bags at security checkpoints in four countries. The US Department of Homeland Security (DHS) recognizes the value of Syntech ONE and has granted Synapse Technology Corporation a SAFETY Act award for its technology platform. For more information, visit synapsetechnology.com.

About Federal Resources

Founded in 1986, Federal Resources is a leading provider of quality products and mission-critical solutions that support the U.S. Military, Federal Government, State/Local Responders, and International Markets. Specializing in comprehensive life-cycle sustainment solutions; procurement and acquisition; technical services and asset management; and training expertise, the organization is dedicated to serving its diverse range of well-established and emerging market segments. Federal Resources strives to fulfill and expand upon its mission to ensure end-users are equipped with the most innovative, reliable, and cost-effective products and technologies available on the market.

For more information, please visit http://www.federalresources.com

About In-Q-Tel

In-Q-Tel (IQT) is the not-for-profit strategic investor that accelerates the development and delivery of cutting-edge technologies to U.S. intelligence and defense agencies that keep our nation safe. IQT was established in 1999 with a distinct mission: to identify and partner with startup companies developing innovative technologies that protect and preserve our nation’s security. Visit http://www.iqt.org for more information.

Share article on social media or email:

Worldwide Online Survey Aims to Identify a New Comprehensive Approach to Global Collaboration for Parkinson’s Disease


https://www.prweb.com/

International Congress of Parkinson’s Disease and Movement Disorders®

It is becoming increasingly clear that even relatively common diseases like PD are highly etiologically heterogeneous syndromes and that progress towards early diagnosis and causative treatments will depend on the identification of sufficient numbers of well-defined subgroups.

A worldwide online survey identifying genetic Parkinson’s disease (PD) patients demonstrates an overall need for global collaboration and new comprehensive approaches for PD, according to research released today at the International Congress of Parkinson’s Disease and Movement Disorders®.

The systematic online survey, developed by members of the Michael J. Fox Foundation Global Genetic Parkinson’s Study Group, collected demographic, clinical and genetic data from PD patients with specific genetic mutations. Using authors from articles represented in the MDSGene database as well as the GEoPD consortium, 336 researchers were identified worldwide to participate in the survey, of which 162 (48%) responded. Overall, 103 international sites in 43 countries reported 8,453 PD patients of more than 9 ethnicities with the genetic mutations. This is particularly significant given that the survey identified a three-fold higher number of patients with genetic PD when compared to the cases reported in the literature, indicating access to patients and data requires new approaches and means of communication.

Thomas Gasser, Director at the Department of Neurodegeneration at Hertie Institute for Clinical Brain Research, in Tuebingen, Germany, states “This initiative is of high relevance because it is becoming increasingly clear that even relatively common diseases like PD are highly etiologically heterogeneous syndromes and that progress towards early diagnosis and causative treatments will depend on the identification of sufficient numbers of well-defined subgroups. This will only be possible by collaborations at a very large, preferably worldwide scale.”

Gasser adds, “Of course, this survey is only a very first small step. If international team science is to become successful, many problems concerning standardization of patient ascertainment, data privacy and protection as well as data access and use need to be solved. Nevertheless, the survey raises awareness of these issues and it clearly shows that the PD research community is ready to begin to tackle these important issues.”

About the International Congress of Parkinson’s Disease and Movement Disorders®: Meeting attendees gather to learn the latest research findings and state-of-the-art treatment options in Movement Disorders, including Parkinson’s disease. Over 5,100 physicians and medical professionals from more than 95 countries will be in attendance to view 2, 200 scientific abstracts submitted by clinicians from around the world.

About the International Parkinson and Movement Disorder Society:

The International Parkinson and Movement Disorder Society (MDS), an international society of over 8,500 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit http://www.movementdisorders.org.

Share article on social media or email:

Modere Inside-Out Beauty System Delivers 360°, Scientifically Advanced Approach to Natural Radiance


https://www.prweb.com/

CellProof Essentials Collection

The Modere® Inside-Out Beauty System combines the company’s patented, award-winning collagen/HA nutraceutical Liquid BioCell® with the CellProof® Essentials Collection, a new trio of topical skincare essentials designed to augment the company’s recent viral hit, CellProof™ Serum.

On Saturday, September 21, Modere®, a healthy, safe and clean-lifestyle brand of dietary supplements, household and personal-care products with a presence worldwide, announced the North American launch of the Modere® Inside-Out Beauty System at their Fall Summit in Orlando, Florida. The Modere® Inside-Out Beauty System combines the company’s patented, award-winning collagen/HA nutraceutical Liquid BioCell® with the CellProof® Essentials Collection, a new trio of topical skincare essentials designed to augment the company’s recent viral hit, CellProof™ Serum.

The Modere ® CellProof™ Essentials Collection is comprised of CellProof™ Serum, CellProof™ Moisturizer, and CellProof™ Infusion Mask. CellProof™ Serum is an age-defying formula powered by BioCell Collagen® CG, recipient of the Frost & Sullivan Award for Best Collagen Peptide in Personal Care, and is backed by multi-patented Collagen/HA Matrix® Technology, a natural matrix of collagen peptides and hyaluronic acid that is Bio-Optimized™ for maximum effectiveness. The cosmetic-grade technology is combined in CellProof™ Serum with a potent botanical complex and Vitamin C to hydrate, firm, and visibly lift the appearance of dull, dry skin in minutes.

CellProof™ Moisturizer also delivers BioCell Collagen® CG to the skin to hydrate and reduce the appearance of wrinkles. Furthermore, the nourishing formula provides the naturally derived antioxidant astaxanthin, a blend of advanced peptides, Vitamin C, and exotic fruit extracts to support healthy-looking skin and a more even skin tone. Decadent cocoa and shea butter leave skin exceptionally smooth, intensely hydrated, and velvety soft.

CellProof™ Infusion mask, which rounds out the collection, is curated with skin-reviving ingredients such as Ox3™, a proprietary compound that releases oxygen bubbles on contact to waken the skin and make way for two rare botanical extracts, Snow Algae and Summer Snowflake Bulb, to renew the skin. Snow Algae and Summer Snowflake work in tandem to help reduce the appearance of fine lines and wrinkles, giving skin a fresh, vibrant look.

In an ultimate, 360° approach to radiant, youthful-looking skin, Modere has magnified the power of its beauty-boosting, award-winning, patented Collagen/HA Matrix® Technology by pairing the new, topical CellProof™ Essentials Collection with its internally nourishing Liquid BioCell® supplement line. Consumers can choose to complement their skincare regimen with any of Modere’s four Liquid BioCell® supplements, Liquid BioCell® Life, Pure, Skin, or Sport. All four products are scientifically shown to deliver Collagen/HA Matrix® Technology to the skin and connective tissues in an ideal molecular weight that the body can effectively absorb. Their individual formulas differ according to the conditions they are designed to target. Liquid BioCell® Life mitigates the joint discomfort and visible signs of advancing age; Liquid BioCell® Pure, Life’s sister supplement, meets the need of consumers with dietary restrictions; ingredients in Liquid BioCell® Skin bolster the benefits for lustrous, unlined skin; and Liquid BioCell® Sport contains NSF certified factors like BCAAs, L-carnitine, and Rhodiola and astragalus extracts to support optimal physical and mental performance.

Asma Ishaq, CEO of Modere, was on hand at the company’s North America Fall Summit to announce the launch: “Beauty is an inside job, a job our ingestible super nutraceutical, Liquid BioCell, does exceedingly well. Sometimes, though, we want to boost that inner shine. The Modere Inside-Out Beauty System does just that by pairing Liquid BioCell with the new CellProof Essentials Collection in an exclusive 360° approach.”

About Modere

Modere (http://www.modere.com) offers a category-leading portfolio of live clean lifestyle essentials including beauty and personal care, health and wellness, and household products that are equal parts safe, high-performing and scientifically designed. We believe modern health involves pure nutrition, a clean environment and safe ingredients across all our product categories. Modere brings a holistic, live clean approach to well-being, and our products reflect a commitment to excellence and innovation with tested formulas proven around the globe. The recipient of multiple third-party validations, our line includes products that are EPA Safer Choice-approved, EWG Verified™, NSF Certified and gray-water safe. The company is a proud supporter of Vitamin Angels®.

Contact: Mara Quigley

Steve Allen Media

mara@steveallenmedia.com

661.255.8283

Share article on social media or email:

Avalon Realty Associates Sponsors First GRIN2B Foundation Cocktail Reception Fundraiser


Avalon Realty Associates logo.

Avalon is proud to support the GRIN2B Foundation and happy to assist in an effort to help individuals and families impacted by GRIN2B.

Avalon Realty Associates – a full service commercial real estate company – has announced it will be one of the sponsors of GRIN2B Foundation’s first cocktail reception fundraiser, Gather for GRIN2B. The event will be held at Found Kitchen and Social House in Evanston on Monday, October 7 from 6 p.m. to 9 p.m.

Proceeds from the benefit will fund research on GRIN2B-Related Neurodevelopmental Disorder, which is caused by variations on the GRIN2B gene.

“Avalon is proud to support the GRIN2B Foundation and happy to assist in an effort to help individuals and families impacted by GRIN2B,” said Carlo Santucci, partner at Avalon Realty Associates.

GRIN2B is a gene on the short arm of the 12th chromosome. It’s part of a family of seven genes that encode proteins to form a receptor that relays chemical messages between neurons in the brain, according to GRIN2B Foundation. Individuals affected by a GRIN2B variation can experience developmental delays, speech delay or lack of speech, and low muscle tone, among other symptoms. Associated conditions can also include seizures, cortical visual impairment, Autism Spectrum Disorders, Attention Deficit Hyperactivity Disorder, and/or intellectual disabilities.

The GRIN2B Foundation is a parent-run organization committed to furthering research on the GRIN2B gene and to providing support for individuals and families affected by variations on the gene.

Some other corporate sponsors of Gather for GRIN2B include Stratosphere Networks, Little Steps Pediatric Therapy, Accounting Concepts, Lubin Austermuehle, P.C., and Rothman Law Group.

To get more information about Gather for GRIN2B and purchase tickets, please visit http://www.grin2b.org/Gather-For-GRIN2B/. Sponsorship information is available at http://grin2b.org/sponsor.

About Avalon Realty Associates

Avalon Realty Associates is a full service commercial real estate company that provides real estate brokerage, property investment, tenant representation and property management. For over 25 years, we’ve built trusting relationships with clients and partners and proudly provide real estate services throughout the country and to our community in the Chicago metro area. For more information, please visit https://avalonreal.com/.

For more information contact:

Carlo Santucci

847-506-1000

carlo@avalonreal.com

Share article on social media or email:

A New Article Explains How To Avoid Parking Lot Accidents


News Image

“Do not consider that if you are in a well=monitored public parking lot, you are safe. Parking lots accidents have become more common, mainly due to distracted driving”, said Russell Rabichev, Marketing Director of Internet Marketing Company.

Although they may look safe, parking lots can be quite hazardous, especially for inexperienced drivers. Official data from the National Safety Council shows that parking lot accidents are more common than one may think. This happens because many drivers are distracted when entering a parking lot. A fifth of car insurance accidents happen in parking lots. To find out more about car insurance, how to avoid accidents and to get free car insurance quotes, visit http://cheapquotesautoinsurance.com/.

For more info and free quotes, visit http://cheapquotesautoinsurance.com/parking-lots-and-car-accidents/

Distracted driving is the main reason why parking lots have become places where accidents happen frequently. A mall parking lot is usually surrounded by huge, flashy billboards. It is easy to lose focus when you are looking on a big screen where the latest offers and discounts are promoted. Keep focus on the road, park the car, then check the ads from a safe place. Also, turn off the smartphone when driving. Some people finding it amusing to take photos of billboards while they enter the parking lot.

Parking lots become crowded during winter holidays. The upcoming Christmas and New Year’s Eve will certainly bring crowds of people to malls and hypermarkets. This means more cars and pedestrians to worry about. With so many blind spots inside a parking lot, the risk of causing an accident is exponentially increased. Pay attention to existing blind spots and slow down. Also consider installing proximity sensors and blind-spot monitors.

Cheapquotesautoinsurance.com is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

For more information, please visit http://cheapquotesautoinsurance.com/.

Share article on social media or email:

OCT Clinical Trials Appoints Maxime Stevens as Chief Strategy and Development Officer; Poises for Global Expansion


Maxime Stevens

OCT Clinical Trials announced that it has appointed Maxime Stevens as Chief Strategy and Development Officer.

“I look forward to supporting both strategic onward growth and success of the company, and inspiring our people to learn even more, and become even more.” — Maxime Stevens, Chief Strategy and Development Officer, OCT Clinical Trials

OCT Clinical Trials, a leading CRO with operations in Eastern Europe, today announced that it has appointed Maxime Stevens as Chief Strategy and Development Officer. In her role, she is responsible for establishing business development vision, creating roadmaps for global expansion, driving operational excellence and leading short- and long-term global strategy growth operations for the entire company.

“It is both an honor and pleasure for me to be joining OCT Clinical Trials as their Chief Strategy and Development Officer,” Stevens said. “The people are extremely skilled, experienced and passionate about not only our work, but also each other, our sponsors and our partners.”

Maxime brings more than 25 years’ experience in executive leadership, developing Global BD and Operations groups for both American and European companies, including United States Surgical Corporation, Cyberonics Inc., Pierrel Research International AG and Optimapharm. As CEO for Pierrel Research International AG, Maxime was instrumental in wholly restructuring a troubled global company with 28 offices, increasing investments, backlog and revenue pipelines by more than 200%, and securing SIX Swiss Exchange listing of the merged companies in 2014.

Maxime possesses a strong track record of driving long-term growth, operational excellence and expansion of new geographic and channel opportunities for prominent players in the industry. Her extensive international experience, most notably in MENA, Africa, Europe and the United States, is a valuable asset for OCT Clinical Trials as the company moves toward global expansion.

Maxime is also known for her seven-year period running operations for South Africa’s branch of the World Health Organization (WHO). Maxime was recognized by WHO for Outstanding Contribution to Ethics in Business and Humanity, and was an Honored Member of International WHO’s WHO of Professionals in both 2013 and 2014. She also sat for four years on the FDA advisory and ethical boards for Innovative Medical Device approvals.

“I look forward to supporting both strategic onward growth and success of the company, and inspiring our people to learn even more, and become even more. Our best work happens when we embrace making a difference — and then we achieve it,” Maxime added.

Having already gained a sizable market share of trials in Eastern Europe and CIS region, OCT is now taking the significant step of expanding its presence into EMEA, Israel, South Africa, Europe and the United States. With this strategic reinforcement, they will continue to provide the tailor-made solutions they are already known for, now to a broader pool of pharma, biotech and medical device companies.

“We’re a full-service CRO with over 300 projects in our portfolio, solid technological infrastructure and well-run processes with all the main sites within the Eastern European and CIS region,” said Dmitry Sharov, OCT Group President. “We realize that our services and approach are in high demand, not only for sponsors within the region, but for companies worldwide. Maxime Stevens has the proven experience and expertise to strategically develop and drive our expertise into the global arena, and amplify the image of a CRO with an impeccable reputation.”

About OCT Clinical Trials

OCT Clinical Trials is the leading CRO in Russia, with operations in Central and Eastern Europe and the CIS region. With a team of over 200 professionals, the company provides a full range of high-quality clinical research services for phase I-IV and BE studies. With strong local expertise and focus on quality, OCT ensures seamless clinical trial conduct and drug registration on time and within budget. OCT’s experienced team delivers both standalone services such as medical writing, consultancy, project management/monitoring, data management/biostatistics and turnkey service for clinical development. Since 2005, OCT Clinical Trials has worked on over 300 full-service and functional service projects in more than 20 therapeutic areas. Learn more at http://www.OCT-ClinicalTrials.com.

Share article on social media or email:

Mattax Neu Prater Eye Center Now Offering First Trifocal Lens for Cataract Patients


Jacob Thomas, MD, of Mattax Neu Prater Eye Center

Jacob Thomas, MD, of Mattax Neu Prater Eye Center

It’s truly one-of-a-kind and may be very helpful for those whose lifestyle requires more complete vision.

Mattax Neu Prater Eye Center now offers its cataract patients the AcrySof® IQ PanOptix® Trifocal Lens, the first and only trifocal intraocular replacement lens (IOL) available in the United States. Implanted during cataract surgery, the PanOptix lens is designed to provide a full range of vision with less dependence on glasses and contacts. This full range includes clear vision at near (e.g. looking at a cell phone), intermediate (e.g. looking at a computer screen), and far (e.g. watching television) distances.

“Cataract correction technology is constantly evolving, so our team is always monitoring these advancements,” says eye surgeon Dr. Jacob Thomas of Mattax Neu Prater. “When we select a new device for our patients, it’s because we believe it’s the most beneficial option for them, not simply because it’s the newest. That is why we are so excited to introduce our cataract patients to the PanOptix trifocal lens. It’s truly one-of-a-kind and may be very helpful for those whose lifestyle requires more complete vision.”

Those interested in learning more about the advanced technology PanOptix IOL should request a cataract consultation by calling Mattax Neu Prater Eye Center at (417) 886-3937 or visiting MattaxNeuPrater.com.

ABOUT MATTAX NEU PRATER EYE CENTER

With five locations in Springfield, Lebanon, Monett, Mountain Grove, and Branson, as well as an onsite surgery center within the Springfield office, Mattax Neu Prater serves patients across the Ozarks. Together, they provide surgical, medical, and primary vision care, including:


  • LASIK laser vision correction
  • Laser-assisted cataract correction with advanced replacement lenses
  • Treatment for glaucoma, diabetic retinopathy, macular degeneration, cornea conditions, and dry eyes
  • Comprehensive eye exams, optical services, and contact lenses

To learn more or request an appointment at Mattax Neu Prater Eye Center, call (417) 886-3937 or visit MattaxNeuPrater.com.

Share article on social media or email: